Osteoporosis

  • Prevention and osteoporosis management
    Angelo A. Licata, MD, PhD
    Cleveland Clinic Journal of Medicine November 1994, 61 (6) 451-460;
  • From bathtub ring to osteoporosis: a clinical review of the bisphosphonates
    Angelo A. Licata, MD, PhD
    Cleveland Clinic Journal of Medicine July 1993, 60 (4) 284-290;

    BACKGROUND Etidronate and pamidronate are bisphosphonates, a class of chemical compounds originally used to soften hard water and prevent soap scum. Etidronate was serendipitously found to abate calcification in a child with myositis ossificans progressiva.

    OBJECTIVE Review the basic pharmacology of these compounds, as well as clinical uses of the approved and nonapproved forms.

    DISCUSSION Etidronate is approved for the treatment of hypercalcemia, Paget’s disease of bone, and ectopic calcification, and has been used to treat hyperparathyroidism and nephrolithiasis with limited success. Recently it has been used to treat osteoporosis. Pamidronate is approved to treat hypercalcemia. These two drugs are the only bisphosphonates available in the United States.

    CONCLUSIONS Clinical trials with etidronate have aroused widespread interest in the application of bisphosphonates to treat osteoporosis. Many trials are underway to evaluate these new drugs. More information will be available within the next 5 years.

  • Chemical and histological features of men with osteoporosis
    Angelo A. Licata, MD, PhD, Thomas W. Bauer, MD, PhD and Bernard Stulberg, MD
    Cleveland Clinic Journal of Medicine January 1993, 60 (1) 56-59;

    In this study group, increased parathyroid hormone secretion promoted a chronic high remodeling state which could have led to osteoporosis.

  • Transient osteoporosis of the hip: clinical and imaging features
    Jean Schils, MD, David Piraino, MD, Bradford J. Richmond, MD, Bernard Stulberg, MD, George H. Belhobek, MD and Angelo A. Licata, MD
    Cleveland Clinic Journal of Medicine September 1992, 59 (5) 483-488;

    Radiographic findings are late and sometimes subtle.

  • Management of orthopedic complications of metabolic bone disease
    Bernard N. Stulberg, MD and J. Tracy Watson, MD
    Cleveland Clinic Journal of Medicine October 1989, 56 (7) 696-703;
  • Drug-induced osteoporosis
    Daniel J. Mazanec, MD and Joseph M. Grisanti, MD
    Cleveland Clinic Journal of Medicine May 1989, 56 (3) 297-303;
  • Some thoughts on osteoporosis in women
    Angelo A. Licata, MD, PHD
    Cleveland Clinic Journal of Medicine May 1988, 55 (3) 233-238;
  • Urinary cyclic adenosine monophosphate discriminates subsets of patients with osteoporosis
    Angelo A. Licata, M.D., Ph.D. and Manjula K. Gupta, Ph.D.
    Cleveland Clinic Journal of Medicine December 1986, 53 (4) 345-349;